IL239211B - Anti-a–ntb antibodies and related compositions and methods - Google Patents

Anti-a–ntb antibodies and related compositions and methods

Info

Publication number
IL239211B
IL239211B IL239211A IL23921115A IL239211B IL 239211 B IL239211 B IL 239211B IL 239211 A IL239211 A IL 239211A IL 23921115 A IL23921115 A IL 23921115A IL 239211 B IL239211 B IL 239211B
Authority
IL
Israel
Prior art keywords
ntb
antibodies
methods
related compositions
compositions
Prior art date
Application number
IL239211A
Other languages
English (en)
Hebrew (he)
Other versions
IL239211A0 (en
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of IL239211A0 publication Critical patent/IL239211A0/en
Publication of IL239211B publication Critical patent/IL239211B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL239211A 2012-12-21 2015-06-04 Anti-a–ntb antibodies and related compositions and methods IL239211B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745239P 2012-12-21 2012-12-21
PCT/US2013/077264 WO2014100740A1 (en) 2012-12-21 2013-12-20 Anti-ntb-a antibodies and related compositions and methods

Publications (2)

Publication Number Publication Date
IL239211A0 IL239211A0 (en) 2015-07-30
IL239211B true IL239211B (en) 2020-08-31

Family

ID=50979291

Family Applications (2)

Application Number Title Priority Date Filing Date
IL239211A IL239211B (en) 2012-12-21 2015-06-04 Anti-a–ntb antibodies and related compositions and methods
IL271305A IL271305B (en) 2012-12-21 2019-12-10 Anti-ntb–a antibodies and related compositions and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL271305A IL271305B (en) 2012-12-21 2019-12-10 Anti-ntb–a antibodies and related compositions and methods

Country Status (10)

Country Link
US (4) US9708404B2 (enExample)
EP (1) EP2934585B1 (enExample)
JP (4) JP6449777B2 (enExample)
CN (2) CN105188749B (enExample)
AU (1) AU2013364043B2 (enExample)
CA (1) CA2893977C (enExample)
EA (1) EA031025B1 (enExample)
HK (1) HK1216850A1 (enExample)
IL (2) IL239211B (enExample)
WO (1) WO2014100740A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700141T3 (es) * 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
CA2893977C (en) * 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
CN107074940A (zh) * 2014-09-09 2017-08-18 德州大学系统董事会 针对agr2和其受体c4.4a的阻断性单克隆抗体
KR20170068409A (ko) * 2014-09-16 2017-06-19 이즈 참 리미티드 항-egfr 항체 및 그의 용도
AU2015327064B2 (en) * 2014-09-30 2021-03-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to L1CAM (CD171)
WO2016070089A2 (en) * 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN116063502A (zh) * 2015-06-30 2023-05-05 西雅图基因公司 抗ntb-a抗体和相关组合物以及方法
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
CA3091181A1 (en) * 2018-02-13 2019-08-22 Precision Biologics, Inc. Methods and compositions for targeting treg cells
CA3143087A1 (en) 2019-07-03 2021-01-07 Arnima BISHT Antibodies and methods of use
KR20220079590A (ko) * 2019-10-04 2022-06-13 티에이이 라이프 사이언시스 Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물
WO2021111005A1 (en) 2019-12-06 2021-06-10 Thoas Fioretos Novel agents and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5515508A (en) 1993-12-17 1996-05-07 Taligent, Inc. Client server system and method of operation including a dynamically configurable protocol stack
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2001053466A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Methods and materials relating to semaphorin-like polypeptides and polynucleotides
EP1252333A4 (en) 2000-01-25 2005-01-05 Nuvelo Inc METHODS AND SUBSTANCES RELATING TO CD84-TYPE POLYPEPTIDES AND POLYNUCLEOTIDES
AU2001253362A1 (en) 2000-04-13 2001-10-30 Smith Kline Beecham Corporation Novel compounds
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6464770B1 (en) 2000-08-08 2002-10-15 Advanced Minerals Corporation Perlite products with controlled particle size distribution
AU2002216610A1 (en) 2000-09-01 2002-04-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7795412B2 (en) 2000-09-15 2010-09-14 Genentech, Inc. Nucleic acids encoding PRO6308 polypeptides and related vectors and host cells
EP1223218A1 (en) 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
JP2004533222A (ja) 2001-03-12 2004-11-04 インサイト・ゲノミックス・インコーポレイテッド 免疫グロブリンスーパーファミリータンパク質
AU2002325333B2 (en) 2001-07-19 2008-04-03 Innate Pharma NTB-A, a surface molecule involved in natural killer cells activity
MXPA04001986A (es) 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
CA2476555A1 (en) 2002-02-14 2003-08-21 Nuvelo, Inc. Methods of therapy and diagnosis
EP1572130A4 (en) 2002-07-08 2008-07-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNEAL DISEASES
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
JP2006517094A (ja) 2002-10-22 2006-07-20 ヌベロ， インコーポレイテッド 新規核酸およびポリペプチド
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
AU2006294554B2 (en) * 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
TW200823237A (en) * 2006-08-28 2008-06-01 Nuvelo Inc Antibodies to NTB-A
CN101657306A (zh) * 2007-10-03 2010-02-24 赫尔曼斯·博阿达股份有限公司 手动陶瓷切割机
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
JP2012500815A (ja) 2008-08-29 2012-01-12 シムフォゲン・アクティーゼルスカブ 抗ｃｄ５抗体
CN102333859B (zh) * 2008-09-16 2015-04-22 三井化学株式会社 由来自植物的原料生产乳酸的方法及生产乳酸的细菌
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
BRPI1012321A8 (pt) 2009-06-17 2016-09-27 Abbott Biotherapeutics Corp Anticorpos anti-vegf e seus usos
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US8303093B2 (en) * 2009-12-15 2012-11-06 Xerox Corporation Print head having a polymer layer to facilitate assembly of the print head
EP2526115B1 (en) 2010-01-18 2018-08-01 Novo Nordisk Health Care AG Purification of blood coagulation factors
UA108227C2 (xx) * 2010-03-03 2015-04-10 Антигензв'язуючий білок
BR112012026021B1 (pt) 2010-04-15 2022-05-03 Progenics Pharmaceuticals, Inc Anticorpos, seus fragmentos de ligação ao antígeno e seus usos, composições e uso das mesmas, linhagem de células de hibridoma, kit, ácido nucleico, e vetor de expressão
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
KR101962483B1 (ko) * 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
BR112013012138B1 (pt) 2010-11-22 2022-02-22 Innate Pharma Sa Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
HRP20180858T1 (hr) 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CA2893977C (en) * 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
CN116063502A (zh) * 2015-06-30 2023-05-05 西雅图基因公司 抗ntb-a抗体和相关组合物以及方法

Also Published As

Publication number Publication date
US20170320944A1 (en) 2017-11-09
CN105188749A (zh) 2015-12-23
EA031025B1 (ru) 2018-11-30
EP2934585B1 (en) 2018-06-13
CA2893977A1 (en) 2014-06-26
CN105188749B (zh) 2017-12-19
US20230105802A1 (en) 2023-04-06
EA201591191A1 (ru) 2015-11-30
JP6449777B2 (ja) 2019-01-09
JP6817674B2 (ja) 2021-01-20
AU2013364043A1 (en) 2015-06-18
AU2013364043B2 (en) 2018-01-04
US20190375841A1 (en) 2019-12-12
IL271305B (en) 2021-01-31
CN107880126A (zh) 2018-04-06
JP2019014752A (ja) 2019-01-31
CN107880126B (zh) 2021-03-30
HK1216850A1 (zh) 2016-12-09
US10435468B2 (en) 2019-10-08
US20150376276A1 (en) 2015-12-31
EP2934585A4 (en) 2016-07-13
CA2893977C (en) 2024-02-13
EP2934585A1 (en) 2015-10-28
WO2014100740A1 (en) 2014-06-26
JP2016503067A (ja) 2016-02-01
JP2022066565A (ja) 2022-04-28
IL239211A0 (en) 2015-07-30
JP2020055870A (ja) 2020-04-09
IL271305A (en) 2020-01-30
US9708404B2 (en) 2017-07-18

Similar Documents

Publication Publication Date Title
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL266893B (en) Meditops and Meditop binding antibodies and their use
IL259436A (en) Antibodies against 3angptl and their uses
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
ZA201502880B (en) Compositions and methods for immunotherapy
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
IL254416B (en) Anti-asic1 antibodies and their uses
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
IL234695B (en) Antigen compositions and methods
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
SI2830587T1 (sl) Sestavek za zaščito in uravnoteženje kože
GB201208372D0 (en) Antibodies and uses thereof
GB201116340D0 (en) Compositions and methods
GB201209584D0 (en) Modified antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed